Litsea

Litsea: A Comprehensive Reference

1. Identity and Botanical Classification

Taxonomy and Nomenclature

The genus Litsea is one of the most diverse genera of evergreen trees or shrubs belonging to the family Lauraceae, and comprises roughly 400 species distributed abundantly throughout tropical and subtropical Asia, North and South America. The most commercially and medicinally prominent species is Litsea cubeba (Lour.) Pers., which carries several common names reflecting its geographic and cultural range: it is sometimes referred to as the aromatic litsea, may chang, mountain pepper (shānhújiāo, 山胡椒), mujiangzi (木姜子), or douchijiang (豆豉姜) in Mandarin, and maqaw (馬告) by the Atayal people of Taiwan. Other commercially relevant species within the genus include Litsea glutinosa, Litsea japonica, Litsea glaucescens, and Litsea mollis, though L. cubeba is the principal source of commercial essential oil and the most extensively studied.

Morphology and Geographic Distribution

Litsea cubeba is a species of evergreen tree in the family Lauraceae, growing as a shrub up to 5–12 meters high. It is native to Assam, Bangladesh, Borneo, Cambodia, South-Central and Southeast China, the East Himalaya, Hainan, Japan, Java, Laos, Malaysia, Myanmar, Nansei-shoto, Nepal, Sumatra, Taiwan, Thailand, Tibet, and Vietnam. Seventy-four plant species of this genus have been found in China alone, most growing in the regions between 18° and 34° north latitude in Southern and Southwest China, including Anhui, Zhejiang, Fujian, Yunnan, Sichuan, and Tibet provinces.

Common Forms and Preparations

The plant is commercially exploited in several distinct forms:

• Essential oil (LCEO): Essential oil yields from the fruit are 3–5%. The oil's main component is citral, at 70–85% of the oil. The oil is obtained by hydrodistillation or solvent-free microwave extraction of fresh or dried fruits.
• Crude plant part extracts: Different extracts from plant parts, such as bark, leaf, root, and fruits, have been utilized in traditional Chinese medicines for curing various diseases.
• Culinary/food ingredient: The fresh green fruit is used for culinary purposes such as salad preparation, chutneys, and pickles.
• Industrial raw material: The essential oil is used as a flavor enhancer in foods, cosmetics, and cigarettes; as a raw material in the manufacture of citral, vitamins A, E, and K, ionone, methyl ionone, and perfumes; and as an antimicrobial and insecticide.

China is the largest producer and exporter of LCEO in the world, with an estimated production of 1,500–2,000 tonnes per annum.

2. Traditional and Historical Use

Traditional Chinese Medicine (TCM)

Different species of the genus Litsea have been used as traditional herbal medicines since 600 A.D. and as sources of important secondary metabolites. In the aspect of ethnomedicine, 20 plants in Litsea species have a long history of use in traditional and indigenous Chinese medicines. The fruit is the commonly prescribed medicinal part for the treatment of gastrointestinal diseases, pain, asthma, and traumatic injury. Meanwhile, the leaves, stems, velamina, roots, and barks have also been adopted to treat people suffering from stomachache, cold, pain, arthritis, diarrhea, and traumatic injury.

Twenty plants of the genus Litsea are found to be important traditional medicines in China, with a long medicinal application for diarrhea, stomachache, dyspepsia, gastroenteritis, diabetes, edema, cold, arthritis, asthma, pain, and traumatic injury. The Traditional Chinese Medicine pharmacopoeia (Zhonghua Bencao) formally documents these species and their preparations.

Indigenous Traditions in Taiwan

Litsea cubeba, also named Makauy by indigenous peoples, is a traditional herb used as a cooking condiment or for tea brewing to treat diseases among aboriginal communities in Taiwan. The Atayal people, in particular, have an extensive tradition of using the maqaw fruit and plant as a seasoning, in ceremonial contexts, and medicinally.

South and Southeast Asia

Litsea species have been used globally in traditional medicine for the treatment of various diseases including influenza, stomach aches, diarrhea, diabetes, vomiting, bone pain, inflammation, illness related to the central nervous system and other ailments. In Taiwan, plant extract is used to treat athlete's foot and other skin diseases, and in Indonesia, fruits are used as a substitute for cubeb pepper (Piper cubeba L.). Native Litsea species, such as L. cubeba, L. japonica, and L. salicifolia, are important traditional medicinal plants that provide sources of spices and food, used to treat various diseases including diarrhea, vomiting, bone pain, asthma, and traumatic injury, in the traditional medicine systems of China, Japan, India, Korea, and Vietnam.

Traditional Preparations

In traditional contexts, preparations included decoctions and infusions of fruits, leaves, bark, and roots; topical application of extracted oils; and use of the fresh fruit directly in cooking. Ethnobotanical records describe its medicinal purposes as carminative (relieves flatulence), diuretic (aids urine passage), expectorant (aids secretion of sputum), stimulant, antiasthmatic, sedative, and antidysenteric, among others.

3. Key Constituents and Active Compounds

Essential Oil Volatiles

The essential oil of L. cubeba fruit is dominated by monoterpene aldehydes. The overall essential oil content, obtained by hydrodistillation and analyzed by GC-MS, ranged from 3.04% to 4.56%. In total, 59 compounds were identified, the dominant components being monoterpenes (94.4–98.4%), represented mainly by neral and geranial (78.7–87.4%). Specifically, the main components of the essential oil were identified as E-citral (geranial) (27.49%), Z-citral (neral) (23.57%), and D-limonene (18.82%), followed by β-thujene (3.34%), β-pinene (2.85%), α-pinene (2.57%), 6-methyl-5-hepten-2-one (2.40%), and linalool (2.36%).

In general, citral is the dominant chemical in fruit LCEO, supported by the majority of current literature. However, leaf LCEO appeared to mainly consist of 1,8-cineole, as shown in Vietnamese samples; Indian leaf LCEO carries sabinene (up to 59%) and α-pinene (up to 13%) as major constituents. These results demonstrate significant regional variation in the chemical composition of LCEO.

By analyzing LCEO extracted from fruits of 32 provinces, seven compounds were detected as dominant: citral, D-limonene, 3,7-dimethyl-3,6-octadienal, 4-methyl-3-pentenal, linalool, citronellal, and 1-(cyclopropanecarbonyl)piperidin-4-one.

Non-Volatile Phytochemicals

Beyond the volatile fraction, the genus Litsea is phytochemically rich. Over 200 ingredients have been identified from the 20 Litsea species used in TCM, and flavonoids, terpenoids, and alkaloids are considered the characteristic and bioactive constituents. The major groups of compounds include alkaloids, monoterpenes, sesquiterpenes, diterpenes, flavonoids, amides, lignans, steroids, and fatty acids.

Different types of lignans have been reported in Litsea species. To date, 35 lignans have been extracted from various species including L. cubeba, L. chinpingensis, L. euosma, L. glutinosa, L. grandis, and others.

Alkaloids: Several aporphine-type alkaloids have been isolated from L. cubeba, most notably boldine and reticuline. Over the past decade, boldine, a naturally occurring alkaloid found in several plant species, has garnered attention for its efficacy in rodent models of human disease. Some properties attributed to boldine include antioxidant activities, neuroprotective and analgesic actions, hepatoprotective effects, anti-inflammatory actions, cardioprotective effects, and anticancer potential. A novel isoquinoline alkaloid named litcubanine A has also been isolated: litcubanine A (LA) was first obtained and elucidated from L. cubeba.

Mechanisms of Action of Key Constituents

Citral (geranial + neral): Citral, a major component of LCEO, showed robust binding to IL-1β, IL-6, and TNF-α, exerting anti-inflammatory effects through hydrogen bonding interactions. Citral exhibits bacteriostatic activity against methicillin-resistant Staphylococcus aureus (MRSA), and the activity is antagonistically modulated by accompanying components.

Anti-inflammatory alkaloids: An in vitro study indicated that litcubanine A could significantly inhibit LPS-induced activation of inflammatory macrophages via the NF-κB pathway, leading to the decrease of inflammatory factors including iNOS, TNF-α, and IL-1β. Moreover, litcubanine A showed an inhibiting effect on the expression of NO in macrophages by directly binding to iNOS protein.

Boldine: Compelling data indicate that boldine blocks connexin (Cx) hemichannels (HCs), and many of its effects in rodent models of injury and disease may be due to this CxHC blockade.

Anti-inflammatory (roots and stems): Compounds isolated from roots and stems of L. cubeba showed significant inhibitory activity against nitric oxide (NO) production in lipopolysaccharide (LPS)-induced murine microglial (BV-2) cell lines. Additional compounds exhibited significant neuroprotective effects against hydrogen peroxide-induced oxidative damage in rat adrenal pheochromocytoma (PC12) cell lines.

Antibacterial mechanism: The L. cubeba oil showed a moderate antibacterial effect on E. coli with antibacterial and rapid bactericidal effects. The presence of aldehydes accounted for its antibacterial effects (approximately 70% of the total composition), with the minor components producing a synergistic antibacterial effect.

4. Scientific Evidence by Area of Use

4.1 Antimicrobial and Antifungal Activity

This is among the most extensively investigated pharmacological properties of L. cubeba essential oil. The essential oil extracted from L. cubeba has broad-spectrum antimicrobial activity and high antioxidant properties, with great potential for increased usage in the food industry.

Wang and Liu studied the minimum inhibitory concentrations (MICs) of oils from different parts of Litsea cubeba on Bacillus subtilis, Enterococcus faecalis, Escherichia coli, Monilia albicans, Pseudomonas aeruginosa, and Staphylococcus aureus, and found the oils had moderate antimicrobial activity.

Antibacterial activities have been reported against bacterial pathogens including methicillin-resistant Staphylococcus aureus, Vibrio parahaemolyticus, Listeria monocytogenes, and Streptococcus garvieae. LCEO's antibacterial activity against MRSA has been reported. The destructive effect of LCEO on MRSA cytomembrane was confirmed by TEM testing and subsequently validated through qualitative and quantitative investigation.

For antifungal activity, the antimicrobial activity of Litsea resinosa and L. elliptica essential oils from roots was evaluated by agar well diffusion assay and mycelial radial growth assay. The oils showed significant antifungal activities with inhibition rates of 80.11% and 66.85%, respectively. The antifungal and antimicrobial effects of Litsea EO have been investigated against several food pathogenic microbes such as Fusarium verticillioides, F. graminearum, and E. coli.

Evidence characterization: The antimicrobial evidence for LCEO is predominantly in vitro (laboratory-based MIC studies, disc diffusion assays), with some in vivo animal studies. No controlled human clinical trials on antimicrobial endpoints have been identified in the peer-reviewed literature. The evidence is therefore preliminary and preclinical.

4.2 Anti-inflammatory Activity

LCEO exhibited protective effects on colonic tissue by protecting crypts and maintaining epithelial integrity, and anti-inflammatory properties by reducing TNF-α, IL-6, and IL-1β levels in the liver and intestine. This study was conducted in an animal model of intestinal inflammation. Research suggests that LCEO may be a promising natural compound for ameliorating diarrhea and intestinal inflammation, with potential implications for modulating the gut microbiome.

At the immunological level, LCEO was shown to decrease the production of TNF-α and cytokine IL-12 in a dose-dependent manner in LPS-stimulated dendritic cells. Contact hypersensitivity (CHS) response and infiltrative T cells were inhibited in the tested ears of mice co-treated with LCEO. These findings demonstrated that LCEO, mainly containing citral, exhibits an immunosuppressive effect on dendritic cells and mice, indicating that LCEO could potentially be applied in the treatment of CHS, inflammatory diseases, and autoimmune diseases.

Yang et al. (2018) demonstrated the in vivo anti-inflammatory effect of boldine and reticuline in models of xylene-induced ear edema as well as carrageenan-induced paw edema.

Evidence characterization: Anti-inflammatory evidence for L. cubeba and its constituents rests almost entirely on in vitro cell assays and rodent models. No human clinical trials assessing anti-inflammatory endpoints have been located in the peer-reviewed literature. Evidence is preclinical and preliminary.

4.3 Antidiabetic Activity

Experimentation on diabetic model rats revealed potent antidiabetic and antihyperlipidemic activities of fruits of L. cubeba. Metabolic profiling by LC-MS showed the presence of a major bioactive principle that might synergistically act against diabetic complications. Network pharmacological analysis showed the interaction of these active molecules with several potential disease target proteins associated with diabetes and interconnected via several cellular signaling pathways.

Boldine, a potent antioxidant found in Litsea and other plants, possesses several health-promoting properties including anti-inflammatory, antitumor, antidiabetic, and cytoprotective activities. Treatment with boldine (50 mg/kg/day) was found to prevent renal alterations in rats with streptozotocin-induced diabetes, including hyperglycemia, hypertension, and renal damage.

Evidence characterization: Antidiabetic evidence is derived from animal models (streptozotocin-induced diabetic rats) and network pharmacology analyses. No human clinical trials have been identified. This evidence is preclinical.

4.4 Antioxidant Activity

The crude extracts and isolated metabolites of medicinal Litsea plants have exhibited in vitro and in vivo pharmacological effects including antioxidant activity, among others. In recent years, LCEO has demonstrated antioxidant properties in laboratory testing. One study of fruit and leaf EO from northeastern India found excellent scavenging activity with IC₅₀ values of 0.9803 μg/mL and 2.819 μg/mL for the respective oils, though this study also noted regional compositional variation affecting activity.

Evidence characterization: Antioxidant data are exclusively from in vitro radical scavenging assays (DPPH, ABTS, and similar). No clinical human trials have been identified. Evidence is preclinical.

4.5 Anticancer Activity

The alkaloid boldine potently inhibited the viability of human invasive breast cancer cell lines MDA-MB-231 (48-h IC₅₀ of 46.5 ± 3.1 μg/mL) and MDA-MB-468 (48-h IC₅₀ of 50.8 ± 2.7 μg/mL).

In vitro cytotoxicity assays revealed promising anticancer activity against prostate cancer PC3 cells (IC₅₀ of 141.2 μg/mL). Complementary toxicity screening in zebrafish embryos confirmed minimal developmental toxicity and negligible impact on cardiac function at therapeutic concentrations, although moderate irritation potential was noted via the HET-CAM assay.

A cytotoxicity study of methanolic extract of mixed-leaves of L. elliptica showed significantly higher cytotoxicity than young-leaf extract against the A549 lung cancer cell line at 24 and 48-hour treatment periods.

Evidence characterization: All anticancer evidence is from in vitro cell line assays and limited zebrafish developmental models. No in vivo mammalian tumor models with L. cubeba as a whole are reported. No human trials exist. Evidence is at the most preliminary, exploratory stage and cannot be extrapolated to clinical efficacy.

4.6 Neuroprotective Activity

Compounds isolated from roots and stems of L. cubeba exhibited significant neuroprotective effects against hydrogen peroxide-induced oxidative damage in the rat adrenal pheochromocytoma (PC12) cell line. The fruit of Litsea lancilimba Merr. yielded 20 recognized sesquiterpenes and four previously unidentified sesquiterpenes. The neuroprotective effects of each substance against H₂O₂-induced SH-SY5Y cell injury were examined, and five substances showed equivalent neuroprotective efficacy to the effective control Trolox at 50 μM.

Additionally, a study on Litsea glaucescens, a related species, identified the antidepressant potential of its essential oil: antidepressant activity of Litsea glaucescens essential oil was reported in the Journal of Ethnopharmacology, with β-pinene and linalool identified as active principles.

Evidence characterization: Neuroprotective evidence is exclusively from in vitro cell culture models. No human trials have been identified.

4.7 Immunomodulatory Activity

An immunosuppressive activity of LCEO was investigated using bone marrow-derived dendritic cells (DCs), which have a critical role in triggering adaptive immunity. Additionally, the inhibitory effect of LCEO on immune response was elucidated by performing contact hypersensitivity (CHS) responses in mice. Results showed that the amounts of TNF-α and IL-12 produced by LPS-induced DCs were inhibited by the presence of LCEO in a dose-dependent manner.

Evidence characterization: All immunomodulatory data originate from in vitro cell assays and mouse contact hypersensitivity models. No human trials have been conducted.

4.8 Gut Microbiome and Gastrointestinal Effects

Using community barplot and LEfSe analyses, researchers detected significant variation in microbial composition, identified discrete biomarkers, and highlighted the influence of essential oils on gut microbial communities. The research suggests that LCEO may be a promising natural compound for ameliorating diarrhea and intestinal inflammation, with potential implications for modulating the gut microbiome.

Chen et al. demonstrated that supplementing LCEO in feed improved growth performance and physiological and biochemical indicators in pigs, while also enhancing the body's antioxidant capacity and nutrient digestion and absorption efficiency. This represents animal (swine) feeding trial data rather than human evidence.

Evidence characterization: Gastrointestinal evidence consists of animal feeding trials and rodent models of colitis. Traditional use for gastrointestinal ailments is well documented historically, but clinical human trial evidence is absent.

4.9 Musculoskeletal and Anti-Arthritic Activity

Research has shown the potential of boldine (an isoquinoline alkaloid extracted from the roots of Litsea cubeba) in improving the micro-architecture of bone in arthritis. Although the effect of boldine in rheumatoid arthritis remains unclear, boldine has demonstrated potential for suppressing inflammatory responses and protecting bone, without adverse effects on the liver or kidney.

Evidence characterization: These data are from collagen-induced arthritis animal models. No human trials have been identified.

4.10 Insecticidal and Pest-Repellent Activity

Insecticidal activities, including contact toxicity, fumigant toxicity, and repellent activity, of L. cubeba fruit extracts have been investigated against Sitophilus zeamais (maize weevil). These results indicate that L. cubeba fruit extracts possess natural insecticide-like activities against S. zeamais. This activity is primarily attributed to the monoterpene aldehyde constituents, particularly citral. This application, while well-supported in the laboratory, falls outside the domain of human health supplementation.

5. Body Systems and Health Areas Associated with Litsea

Based on the reviewed literature, the following body systems are associated with Litsea research:

• Gastrointestinal system: Historically and in preclinical models, for diarrhea, dyspepsia, gastroenteritis, and intestinal inflammation.
• Immune system: Modulation of dendritic cell activation, macrophage function, and cytokine production (TNF-α, IL-6, IL-1β, IL-12) in preclinical models.
• Endocrine/metabolic: Antidiabetic and antihyperlipidemic effects in diabetic animal models; traditional use for diabetes.
• Musculoskeletal: Traditional and preclinical evidence for arthritis, bone pain, and traumatic injury; boldine studied in arthritic animal models.
• Nervous system: Neuroprotective cell culture studies; traditional use for CNS-related ailments; antidepressant potential identified in L. glaucescens essential oil components.
• Respiratory system: Traditional use for asthma and cold; no specific clinical studies identified.
• Integumentary system: Application of essential oil for skin conditions (athlete's foot, acne) in traditional medicine; preclinical antimicrobial and whitening data.
• Oncology (exploratory): In vitro cytotoxicity of boldine and whole extracts against several cancer cell lines.

6. Dosage Forms and Reported Dosages

No standardized human clinical dosages have been established, as no controlled human trials have been published for L. cubeba or its constituents as dietary supplements. The following dosages appear in the preclinical literature as reported in source studies:

• Boldine (animal studies): Treatment with boldine at 50 mg/kg/day was used in rat studies examining prevention of renal alterations in streptozotocin-induced diabetic rats.
• Essential oil (in vitro, cosmetic testing): L. cubeba essential oil at the maximal dose of 30% (v/v) exhibited no cytotoxicity on the human gingival fibroblast cell line.
• Essential oil (acute toxicity, rodent): The oral LD₅₀, the dermal LD₅₀, and the inhalation LC₅₀ were determined to be approximately 4,000 mg/kg body weight, in excess of 5,000 mg/kg, and approximately 12,500 ppm, respectively.
• Breast cancer cell line studies (boldine): Boldine inhibited viability of MDA-MB-231 cells with a 48-h IC₅₀ of 46.5 ± 3.1 μg/mL and MDA-MB-468 cells with a 48-h IC₅₀ of 50.8 ± 2.7 μg/mL.
• Prostate cancer cell line study: The L. cubeba leaf ethanol extract exhibited anticancer activity against prostate cancer PC3 cells with an IC₅₀ of 141.2 μg/mL in cytotoxicity assays.
• Acute oral toxicity (leaves, in vivo): L. cubeba leaves at doses up to 5,000 mg/kg caused no mortality or overt toxicity symptoms, including neurological or gastrointestinal disturbances. Observations of stable body weights, food intake, and relative organ weights further supported the extract's safety profile. Biochemical analyses demonstrated normal urea, creatinine, and liver enzyme levels, with only a mild, non-toxic elevation of SGOT observed in female mice at the highest dose.

The Ministry of Health of China has approved LCEO for use as a food additive, though specific permitted concentration limits for this approval were not detailed in the sources retrieved.

7. Safety Considerations and Interactions

Acute Toxicity

In a study on ICR mice and Sprague-Dawley rats, the oral LD₅₀, the dermal LD₅₀, and the inhalation LC₅₀ were approximately 4,000 mg/kg body weight, in excess of 5,000 mg/kg, and approximately 12,500 ppm, respectively. The study concluded that L. cubeba oil is slightly toxic.

Earlier animal data reported by another group noted: the LD₅₀ for intragastric administration was 3.25 mL/kg. Later, the LD₅₀ for intraperitoneal injection was determined to be 381 mg/kg.

Genotoxicity

The genetic toxicity of L. cubeba oil was assessed with Salmonella typhimurium (Ames test), by determination of the induction of micronuclei in bone marrow cells, and also by testing for chromosome aberration in spermatocyte cells of ICR mice. The results of genetic toxicity testing of L. cubeba oil in vitro and in vivo were negative.

This finding is corroborated by OECD-compliant testing: in an OECD guideline-compliant Ames assay, no mutagenicity was observed using both the plate incorporation method at up to 5,000 μg/plate and the pre-incubation method at up to 1,500 μg/plate of Litsea cubeba berry oil in the presence and absence of S9, using S. typhimurium strains TA98, TA100, TA1535, TA1537 and E. coli WP2uvrA.

A separate genotoxicity study from northeastern India on fruit and leaf EO found that genotoxic effects showed LCEO fruit and leaf had negligible effect on root growth inhibition, mitotic index, and chromosome aberration in comparison to the standard ethyl methanesulphonate.

Skin Sensitization and Dermal Safety

The oil of L. cubeba is pungent for skin, leading to skin inflammatory responses in guinea pigs. The high citral content of LCEO is the primary driver of skin sensitization potential. Under the IFRA 51st Amendment, citral is limited to 0.60% in Category 4 (fine fragrance) finished products due to dermal sensitization risk. Since LCEO is 70–85% citral, maximum incorporation of crude oil in an eau de parfum is effectively capped at approximately 0.7–0.9%. European Regulation 2023/1545 also mandates allergen labelling for citral above 0.001% in leave-on products.

Evidence Gaps, Limitations, and Overall Research Status

Based on pharmacological investigations, chemical components, and traditional folk applications, the genus Litsea is considered a medicinal plant having a variety of pharmacological actions. However, although the pharmacological activity has been preliminarily demonstrated, most studies have only been assessed using simple in vitro cell lines or animal disease models. In order to fully elucidate the pharmacological activity and mechanisms, future studies should be conducted in a more comprehensive clinical manner.

The underlying mechanisms and mode of action of many bioactive constituents are not well researched and established. Further in vitro and in vivo genotoxic experiments of Litsea need to be evaluated to substantiate its ethnomedical values.

The underlying mechanism and mode of action are not well researched or established. Further in vitro and in vivo genotoxic experiments of Litsea need to be evaluated to verify its ethnomedical values. The in-depth exploration of Litsea cubeba for its various pharmacological properties can potentially be employed as an initiative to discover new drugs to treat serious diseases like cancer and HIV.

In summary, L. cubeba and the broader Litsea genus have no documented human clinical trials for any health endpoint in the peer-reviewed literature identified at the time of this review. All pharmacological claims rest on traditional use records, in vitro laboratory studies, and preclinical animal research. Many traditional uses of Litsea species have been validated by modern pharmacology research at the preclinical level, but this validation has not yet been extended to human clinical trials. The outcome of future studies will further support the therapeutic potential of the genus and provide convincing evidence for its future clinical applications in modern medicine.

References

• Kong D-G et al. "The genus Litsea in traditional Chinese medicine: an ethnomedical, phytochemical and pharmacological review." Journal of Ethnopharmacology, 2015. PubMed PMID: 25698244
• Zhao Y et al. "Ethnobotany, phytochemistry, and pharmacology of the genus Litsea: An update." Journal of Ethnopharmacology, 2016. PubMed PMID: 26812679
• Kamle M et al. "Ethnopharmacological Properties and Medicinal Uses of Litsea cubeba." Plants, 2019; 8(6):150. PMC6631214
• Chen X et al. "The genus Litsea: A comprehensive review of traditional uses, phytochemistry, pharmacological activities and other studies." Journal of Ethnopharmacology, 2024. PubMed PMID: 38944358
• Liu Y et al. "Litsea cubeba essential oil: Extraction, chemical composition, antioxidant and antimicrobial properties, and applications in the food industry." Journal of Food Science, 2024.
• Si L et al. "Chemical Composition of Essential Oils of Litsea cubeba Harvested from Its Distribution Areas in China." Molecules, 2012. PMC6268156
• Hajšlová J et al. "Role of Litsea cubeba Essential Oil in Agricultural Products Safety: Antioxidant and Antimicrobial Applications." PMC9182909, 2022
• Solvent-Free Microwave Extraction of Essential Oils from Litsea cubeba at Different Harvesting Times and Their Skin-Whitening Cosmetic Potential. PMC9774158, 2022
• Zhang X et al. "Therapeutic potential of Litsea cubeba essential oil in modulating inflammation and the gut microbiome." Frontiers in Microbiology, 2023. PMC10461084
• Li X et al. "Novel Isoquinoline Alkaloid Litcubanine A — A Potential Anti-Inflammatory Candidate." Frontiers in Pharmacology, 2021. PMC8215673
• Chang W-T et al. "Immunosuppressive Effect of Litsea cubeba L. Essential Oil on Dendritic Cell and Contact Hypersensitivity Responses." International Journal of Molecular Sciences, 2016. PMC5000716
• Wang C-Y et al. "Antibacterial Activity and Kinetics of Litsea cubeba Oil on Escherichia coli." PLOS ONE, 2014. PMC4220960
• Antibacterial Activity and Mechanism of Litsea cubeba Essential Oil Against Salmonella typhimurium. PMC12073681, 2025
• Luo M et al. "Acute and Genetic Toxicity of Essential Oil Extracted from Litsea cubeba (Lour.) Pers." Journal of Agricultural and Food Chemistry / ScienceDirect, 2005.
• Li X et al. "Chemical constituents from the roots and stems of Litsea cubeba." Phytochemistry Letters, 2016. PubMed PMID: 26651866
• Bui T et al. "An Update Review of the Litsea genus." Biointerface Research in Applied Chemistry, 2023.
• Gogoi P et al. "A comparative study on antioxidant, anti-inflammatory, genotoxicity, anti-microbial activities and chemical composition of fruit and leaf essential oils of Litsea cubeba Pers from North-east India." Industrial Crops and Products, 2018.
• Zhao H et al. "Boldine isolated from Litsea cubeba inhibits bone resorption by suppressing osteoclast differentiation in collagen-induced arthritis." ResearchGate, 2017.
• Olivera B et al. "Anti-prostate cancer activity of Litsea cubeba ethanol extract." Springer Link, 2025.
• Wikipedia: Litsea cubeba